Trial of Atezolizumab, Bevacizumab, and Tiragolumab in Patients With Microsatellite Stable, Metastatic Colorectal Cancer

• Status: ACTIVE_NOT_RECRUITING
• Trial end date: 2028-05-01

Summary

The goal of this study is to learn if a new combination treatment is effective for patients with microsatellite stable, advanced colorectal cancer. The study treatment combines 3 drugs: atezolizumab, bevacizumab, and tiragolumab. The main questions the study aims to answer are:

1. Does the study treatment effectively treat colorectal cancer?

2. Is the study treatment safe for patients with colorectal cancer?

3. How does the study treatment effect the immune system in patients with colorectal cancer?

Participants in this study will receive the study treatment and undergo checkups, laboratory tests, and imaging tests for monitoring. Some participants will also undergo tumor biopsies.

• Phase: PHASE2

Details

• Lead Sponsor: University of Colorado, Denver
• Collaborator: Genentech, Inc.
• Treatments: atezolizumab; Bevacizumab; Tiragolumab